Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Director | May 08, 2026 | May 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date May 08, 2026 · Filed May 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,563 |
Ending reported balance
After 2026-05-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-08 · Grant · Acquired 1,438 · Balance 4,028 F1: The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders. Row 2 · 2026-05-08 · Grant · Acquired 535 · Balance 4,563 F2: The grant was made in lieu of director service fees for the term commencing May 5, 2026. The restricted stock units vest upon the earlier of 5/8/2027, or the business day prior to the Company's next annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders.
F2: The grant was made in lieu of director service fees for the term commencing May 5, 2026. The restricted stock units vest upon the earlier of 5/8/2027, or the business day prior to the Company's next annual meeting of shareholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2026 Filed May 11, 2026 20:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 535 | $177.62 | $95,026.70 |
DisclosureSEC source: 0001100682-26-000048 · form4.xml · nonDerivative · entry 2 Kemps-Polanco Reshema · CIK 0002009357 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,563 F2 · shares: The grant was made in lieu of director service fees for the term commencing May 5, 2026. The restricted stock units vest upon the earlier of 5/8/2027, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 08, 2026 Filed May 11, 2026 20:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 1,438 | $177.62 | $255,417.56 |
DisclosureSEC source: 0001100682-26-000048 · form4.xml · nonDerivative · entry 1 Kemps-Polanco Reshema · CIK 0002009357 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,028 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 2,076 | $134.98 Strike: $134.98 | $280,218.48 |
DisclosureSEC source: 0001127602-25-015483 · form4.xml · derivative · entry 3 Kemps-Polanco Reshema · CIK 0002009357 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,076 Underlying: Common Stock · 2,076 shares Expires 2035-05-21 F3 · shares: The stock options become exercisable upon the earlier of 5/21/2026 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 630 | $134.98 | $85,037.40 |
DisclosureSEC source: 0001127602-25-015483 · form4.xml · nonDerivative · entry 2 Kemps-Polanco Reshema · CIK 0002009357 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,590 F2 · shares: The grant was made in lieu of director service fees for the term commencing May 20, 2025. The restricted stock units vest upon the earlier of 5/21/2026, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 946 | $134.98 | $127,691.08 |
DisclosureSEC source: 0001127602-25-015483 · form4.xml · nonDerivative · entry 1 Kemps-Polanco Reshema · CIK 0002009357 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,960 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/21/2026 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 13, 2024 Filed May 15, 2024 21:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 1,311 | $228.41 Strike: $228.41 | $299,445.51 |
DisclosureSEC source: 0001127602-24-015523 · form4.xml · derivative · entry 3 Kemps-Polanco Reshema · CIK 0002009357 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,311 Underlying: Common Stock · 1,311 shares Expires 2034-05-13 F3 · shares: The stock options become exercisable upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 13, 2024 Filed May 15, 2024 21:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 285 | $228.41 | $65,096.85 |
DisclosureSEC source: 0001127602-24-015523 · form4.xml · nonDerivative · entry 2 Kemps-Polanco Reshema · CIK 0002009357 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,014 F2 · shares: The grant was made in lieu of director service fees for the term commencing May 8, 2024. The restricted stock units vest upon the earlier of 5/13/2025, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 13, 2024 Filed May 15, 2024 21:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 559 | $228.41 | $127,681.19 |
DisclosureSEC source: 0001127602-24-015523 · form4.xml · nonDerivative · entry 1 Kemps-Polanco Reshema · CIK 0002009357 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 729 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 01:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 399 | $219.54 Strike: $219.54 | $87,596.46 |
DisclosureSEC source: 0001127602-24-003484 · form4.xml · derivative · entry 2 Kemps-Polanco Reshema · CIK 0002009357 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 399 Underlying: Common Stock · 399 shares Expires 2034-02-01 F2 · shares: The stock options become exercisable 5/7/2024. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 01:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 170 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003484 · form4.xml · nonDerivative · entry 1 Kemps-Polanco Reshema · CIK 0002009357 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170 F1 · shares: Consists of 170 unvested restricted stock units that vest on 5/7/2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.